Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity

Table 5 Impacts of lnAUC_gla on sensory nerve function by multivariable linear regression analysis in the T2D/OB group (n = 174)

Models	B (95% CI)	β	t	p	R²
Composite Z score for sensory latency
Model 0	−0.362 (−0.512, −0.213)	−0.342	−4.772	< 0.001	0.117
Model 1	−0.296 (−0.443, −0.148)	−0.279	−3.951	< 0.001	0.314
Model 2	−0.301 (−0.499, −0.103)	−0.266	−3.004	0.003	0.395
Model 3	−0.339 (−0.543, −0.135)	−0.300	−3.291	0.001	0.424
Composite Z score for sensory amplitude
Model 0	0.309 (0.128, 0.490)	0.249	3.366	0.001	0.062
Model 1	0.178 (0.011, 0.344)	0.143	2.105	0.037	0.366
Model 2	0.248 (0.007, 0.490)	0.189	2.042	0.044	0.458
Model 3	0.288 (0.022, 0.554)	0.221	2.151	0.034	0.496
Composite Z score for sensory NCV
Model 0	0.478 (0.309, 0.646)	0.392	5.588	< 0.001	0.154
Model 1	0.314 (0.159, 0.470)	0.258	3.993	< 0.001	0.425
Model 2	0.365 (0.165, 0.565)	0.286	3.611	< 0.001	0.518
Model 3	0.402 (0.197, 0.606)	0.314	3.984	< 0.001	0.551

Model 0: unadjusted
Model 1: adjusted for age, sex, diabetes duration, BMI, SBP, DBP, hypertension and statin treatment
Model 2: additionally adjusted for ALT, albumin, TG, TC, UA, CysC, eGFR, ACR, C-peptide, hemoglobin, glycated albumin, and HbA1c
Model 3: additionally adjusted for hypoglycemic agents
lnAUC_gla natural log-transformed AUC_gla, T2D type 2 diabetes, T2D/OB patients with T2D and obesity, NCV nerve conduction velocity

ISSN: 1758-5996